- RESEARCH HIGHLIGHT
In patients with T cell acute lymphoblastic leukemia, base-edited CAR T cells — capable of destroying leukemic T cells while they themselves are protected — induced remission and allowed progression to stem-cell transplantation.
By
- Karen O’Leary
-
Karen O’Leary is an Associate Research Analysis Editor with Nature Medicine.
-
Patients with T cell acute lymphoblastic leukemia (T-ALL) require allogeneic hematopoietic stem cell transplantation (HSCT) if they relapse or do not respond to standard chemotherapy. But successful HSCT requires deep remission prior to transplantation; without it, the post-transplantation prognosis is poor.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41591-026-00004-8
Related Articles
-
Allogeneic approach unlocks CAR T cell benefits in solid tumors
-
Read more research highlights selected by the Nature Medicine team
